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ABSTRACT As new pathogenic viruses continue to emerge, it is paramount to have
intervention strategies that target a common denominator in these pathogens. The
fusion of viral and cellular membranes during viral entry is one such process that is
used by many pathogenic viruses, including chikungunya virus, West Nile virus, and
influenza virus. Obatoclax, a small-molecule antagonist of the Bcl-2 family of pro-
teins, was previously determined to have activity against influenza A virus and also
Sindbis virus. Here, we report it to be active against alphaviruses, like chikungunya
virus (50% effective concentration [EC50]  0.03 M) and Semliki Forest virus (SFV;
EC50  0.11 M). Obatoclax inhibited viral entry processes in an SFV temperature-
sensitive mutant entry assay. A neutral red retention assay revealed that obatoclax
induces the rapid neutralization of the acidic environment of endolysosomal vesicles
and thereby most likely inhibits viral fusion. Characterization of escape mutants re-
vealed that the L369I mutation in the SFV E1 fusion protein was sufficient to confer
partial resistance against obatoclax. Other inhibitors that target the Bcl-2 family of
antiapoptotic proteins inhibited neither viral entry nor endolysosomal acidification,
suggesting that the antiviral mechanism of obatoclax does not depend on its anti-
cancer targets. Obatoclax inhibited the growth of flaviviruses, like Zika virus, West
Nile virus, and yellow fever virus, which require low pH for fusion, but not that of
pH-independent picornaviruses, like coxsackievirus A9, echovirus 6, and echovirus 7.
In conclusion, obatoclax is a novel inhibitor of endosomal acidification that prevents
viral fusion and that could be pursued as a potential broad-spectrum antiviral candi-
date.
KEYWORDS Zika virus, chikungunya virus, envelope protein, resistant mutant, virus
entry, antiviral
The Alphavirus genus of plus-strand RNA viruses belongs to the Togaviridae familyand includes a number of human pathogens, like Sindbis virus (SINV) and chikun-
gunya virus (CHIKV), and other zoonotic threats, like Venezuelan equine encephalitis
virus. These mosquito-borne viruses cause either polyarthritis or encephalitis and can
result in large-scale outbreaks in immunologically naive populations (1). In recent years,
CHIKV has been in the limelight because of its spread to the Americas and has infected
more than 1.5 million people since 2013 (2). There are no licensed vaccines or
therapeutic drugs currently available to counter these viruses (3).
Semliki Forest virus (SFV) is a relatively less pathogenic well-studied alphavirus. Most
of our knowledge about the composition and structure of the alphavirus particle and
the functions of its different proteins stems from work done with SFV. The alphavirus
particle is 70 nm in diameter and contains a nucleocapsid core surrounded by a lipid
membrane envelope embedded with 80 trimeric spikes, with each spike being made up
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of three E1-E2 envelope protein heterodimers. The E2 envelope protein mediates viral
entry by attachment to cellular receptors, followed by clathrin-mediated endocytic
uptake, which delivers the viral particle to early endosomes. The low-pH environment
of the endosome triggers a sequence of events starting with dissociation of the E1-E2
dimer and conformational changes in the E1 membrane fusion protein. This leads to
insertion of the E1 fusion protein in the target membrane and homotrimer formation,
steps that ultimately result in the formation of a fusion pore and release of the viral
nucleocapsid into the cytosol (reviewed in references 4 and 5). This is followed by the
intracellular steps of the viral infectious cycle, which culminate in progeny virions
budding out from the infected cell.
The low-pH-mediated fusion of viral and cellular membranes is a common theme in
many enveloped viruses from different families and has been explored as a target for
antiviral therapy (6). The influenza A virus (IAV) hemagglutinin requires the low pH of
the endosome for rearrangement and exposure of its fusion peptide (7). The acidic
environment of the endosome also induces conformational changes in the flavivirus E
glycoprotein (8), similar to the findings for alphavirus E1. Some nonenveloped viruses
from the Picornaviridae family, like different strains of the human rhinoviruses and
foot-and-mouth disease virus, also use low-pH cues for the uncoating of their capsid
proteins and genome release, while some others, like poliovirus and coxsackievirus A9
(CV-A9), are pH independent (9, 10). Different classes of acidification inhibitors, like
weak bases, ionophores, and vacuolar proton pump inhibitors, interfere with alphavirus
infection (4) and have been important tools that have helped to decipher the low-pH
requirement in the life cycles of different viruses. Previously, the antimalarial drug
chloroquine, which is capable of elevating the endosomal pH, was shown to possess in
vitro antiviral activity against CHIKV (11) and a number of other viruses, like the severe
acute respiratory syndrome coronavirus (12), HIV, Ebola virus (EBOV) (13), and dengue
virus (DENV). While chloroquine did not offer any protection or added benefit against
CHIKV in rhesus macaques or human clinical trials (14), it has worked better against HIV
in clinical trials (15) and showed in vivo activity against DENV (16) and EBOV (13).
Niclosamide, an anthelminthic drug in clinical use, was described to inhibit the infec-
tion of pH-dependent human rhinoviruses and IAV by a similar mechanism (17) and was
recently also shown to inhibit CHIKV (18). This suggests that the inhibition of endo-
somal acidification represents a target for the development of broad-spectrum antiviral
compounds.
Obatoclax (OLX) is an anticancer compound that antagonizes the prosurvival Mcl-1
protein belonging to the Bcl-2 family of proteins. It triggers apoptosis in cancer cells by
occupying a hydrophobic pocket in the BH3 binding groove of Bcl-2 proteins and
interferes in their interaction with the proapoptotic Bak protein (19). Earlier, Denisova
et al. identified OLX to be an antiviral compound in a targeted screen of host-directed
compounds with activity against reporter IAV infection (20). They proposed that OLX
inhibits IAV entry and uptake by inhibiting Mcl-1. In the same study, proof-of-principle
results showing the antiviral action of OLX on SINV and, to a lesser extent, SFV were
presented (20). Here, we endeavored to thoroughly evaluate the antiviral mechanism of
OLX and show that OLX is equally effective against other alphaviruses, SFV and CHIKV,
at submicromolar concentrations with high selectivity indices. OLX was found to affect
early events in virus infection in an entry assay utilizing the SFV-ts9 temperature-
sensitive mutant. Contrary to the previously proposed mechanism of OLX, we show
here that OLX neutralizes the acidic environment of endocytic organelles and most
likely inhibits the fusion of viral and endosomal membranes. In support of this mech-
anism, an escape mutation in the SFV E1 membrane fusion protein could confer partial
resistance against OLX.
RESULTS
Obatoclax is an antiviral with activity against different alphaviruses. OLX has
previously been shown to act as a novel antiviral drug with activity against IAV. In the
same study, OLX at a low concentration of 0.3 M was suggested to be effective against
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SINV but not against SFV (20). In this study, we tested the activity of OLX against the
reemerging CHIKV and used SINV and SFV as controls. BHK-21 cells were infected with
wild-type SFV, SINV, and CHIKV at a multiplicity of infection (MOI) of 0.01 PFU/cell for
16 h in the presence or absence of 0.5 M OLX. Viral titers from the supernatants of
infected cells indicated that both SINV and CHIKV were inhibited by 5 logs and, contrary
to the findings of the earlier study, SFV was inhibited by 3 to 4 logs (Fig. 1A). Next, we
tested the activity of OLX against CHIKV at a higher MOI of 10 PFU/cell in BHK-21 cells
for 6 h postinfection (p.i.) to assess the effectiveness of the compound in a single
replication cycle. We employed OLX in a 2-fold dilution series at concentrations ranging
from 2 M to 0.125 M in an assay in which OLX was present throughout the infection
and compared the viral titers and the levels of viral RNA and protein synthesis to those
for untreated samples and samples treated with 0.1% dimethyl sulfoxide (DMSO). Viral
progeny production was reduced by 3 logs for the highest concentration tested of 2
M, and a significant reduction was observed even at the lowest concentration tested
of 0.125 M (Fig. 1B). Expression of viral nonstructural and structural proteins was also
severely diminished in a dose-dependent manner at concentrations down to 0.5 M
(Fig. 1C). Viral genomic and subgenomic RNA synthesis was also reduced to a large
extent, with a similar trend of concentration-dependent inhibition being seen (Fig. 1D).
FIG 1 Obatoclax is an effective antiviral against alphaviruses. (A) BHK-21 cells were infected with wild-type SFV, SINV, and
CHIKV at an MOI of 0.01 PFU/cell with or without 0.5 M OLX, which was present throughout the experiment when it was
added. Plaque assay titers in cell culture supernatants collected at 16 h p.i. were determined in duplicate (data are means
from three independent experiments  SEMs). (B) BHK-21 cells were infected with wild-type CHIKV at an MOI of 10 PFU/cell
for 6 h. Throughout the experiment, OLX was present in a 2-fold dilution series at concentrations ranging from 2 M to
0.125 M. Plaque assay titers in cell culture supernatants collected at 6 h p.i. were determined in duplicate (data are means
from three independent experiments  SEMs). Statistical significance was determined using a one-way ANOVA test (****,
P  0.0001). (C) Cell lysates were analyzed by Western blotting for the presence of the indicated CHIKV proteins. Actin was
used as a loading control. (D) Total RNA was isolated from parallel wells, Northern blot analysis was done using probes
specific to the 3= UTR of the CHIKV genome, and the viral genomic and subgenomic RNAs were detected. The results are
representative of those from two independent experiments.
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Overall, these results indicate that OLX is a potent inhibitor of alphaviruses and dose
dependently reduces viral titers and the levels of RNA and protein synthesis even in a
high-MOI setting.
Obatoclax is effective in multiple cell types at submicromolar concentrations.
Next, we assessed if OLX inhibits alphaviruses in multiple cell types. We used reporter
SFV and CHIKV expressing Renilla luciferase (Rluc), and inhibition of the luciferase signal
served as a readout of antiviral activity. Dose-response antiviral activity assays were
performed in BHK-21 cells (MOI, 0.01 PFU/cell), Huh 7.5 cells (MOI, 0.1 PFU/cell), and
HOS cells (MOI, 1 PFU/cell) using OLX at concentrations ranging from 100 M to 0.006
M. The time points used for the assays were chosen on the basis of the luciferase
signals obtained for the different viruses: for BHK-21 cells, SFV and CHIKV were tested
at 16 h; for Huh 7.5 cells, SFV was tested at 12 h and CHIKV was tested at 18 h; and for
HOS cells, SFV was tested at 16 h and CHIKV was tested at 20 h. The concentrations
causing 50% inhibition of viral replication (or the 50% effective concentration [EC50s])
were observed to be at submicromolar levels for OLX against both SFV and CHIKV in the
different cell lines tested (Table 1), with the lowest EC50 of 0.03 M (selectivity index 
670) being obtained against CHIKV in BHK-21 cells (Table 1) (inhibition curves are
shown in Fig. S1 in the supplemental material). Cytotoxicity assays were done in parallel
at the same concentrations to determine the concentration causing a 50% reduction in
cell survival (or the 50% cytotoxic concentration [CC50]) for OLX in the different cell lines
used. OLX showed time-dependent and cell type-specific toxicity, with Huh 7.5 cells
treated for 18 h being the most sensitive (CC50  13.3 M; Table 1). HOS cells were the
least affected by OLX treatment and had a high CC50 value after 16 h of treatment
(102.8 M; Table 1) (cell survival curves are shown in Fig. S2). In summary, OLX is a novel
antiviral with activity against alphaviruses and shows activity at submicromolar con-
centrations.
Obatoclax inhibits the early stages of alphavirus replication. Next, we per-
formed a time-of-addition assay with wild-type SFV and CHIKV to determine the stage
of the viral life cycle being inhibited. In order to ensure that most of the cells were
simultaneously infected, infections were done at an MOI of 1 PFU/cell. A total of 6
different times of addition were used: BHK-21 cells were treated with 0.5 M OLX 2 h
prior to infection, with treatment being continued throughout the course of the
infection; only 2 h before infection; at the time of infection, with treatment being
continued throughout the course of the infection; or at the time of infection but with
OLX being present only during virus adsorption for 1 h p.i. The final two times of
addition were chosen on the basis of the respective virus production curves. For SFV,
OLX was added at 2 h and 4 h p.i. and the cell culture supernatants were harvested 8
h p.i. For CHIKV, the compound was added at 4 h and 8 h p.i. and the cell culture
supernatants were collected 14 h p.i. (a schematic representation of the experimental
layout is shown in Fig. 2A and B). The viral titers obtained in the supernatants of the
respective samples were compared to those in the supernatants of untreated samples
collected at the same time points. For SFV, the reduction in viral titers was most
efficient when the cells were pretreated with OLX or when OLX was added simultane-
ously with the infectious inoculum and treatment with OLX was continued throughout
the course of the infection (Fig. 2C). The inhibition was gradually reduced when the
TABLE 1 EC50s of obatoclax against SFV and CHIKV in different cell lines
Cell line
SFV CHIKV
EC50a (M) CC50b (M) SIc EC50 (M) CC50 (M) SI
BHK-21 0.23  0.02 20.1  4.8 87.4 0.03  0.01 20.1  4.8 670
Huh 7.5 0.11  0.01 42.7  4.7 388.2 0.13  0.01 13.1  3.3 100.8
HOS 0.2  0.06 102.8  15.2 514 0.09  0.01 45.4  9.3 504.4
aEC50, concentration causing 50% inhibition of viral replication.
bCC50, concentration causing a 50% reduction in cell survival.
cSI, selectivity index, which is the ratio of the CC50 to the EC50.
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drug was added at later time points. Strong inhibition was seen when OLX was present
only at early time points and not later, suggesting an effect on the early phase of the
viral life cycle. A similar trend was also seen for CHIKV (Fig. 2D), suggesting that OLX has
a similar mode of action against both SFV and CHIKV. Due to the predominant effect
of OLX on viral titers when it was it was added prior to infection and also when it was
present for only 1 h p.i. during adsorption of the infectious inoculum, we wondered if
OLX could be virucidal in nature, inactivating the virus particle and thereby preventing
the initiation of a productive infection. To this end, an undiluted CHIKV stock was
treated with 0.5 M OLX, 0.1% DMSO (negative control), or 0.1% disinfectant contain-
ing potassium peroxymonosulfate, sodium dodecylbenzenesulfonate, sulfamic acid,
and inorganic buffers (Virkon; positive control) for 30 min at 37°C, followed by plaque
titration on BHK-21 cells. Compared to the significant reduction in titers observed with
0.1% disinfectant treatment, no such difference was seen with OLX treatment (Fig. S3).
Obatoclax inhibits virus entry. Having ruled out any virucidal activity of OLX, the
compound was tested in the previously described SFV entry assay (21) using the
FIG 2 Obatoclax inhibits early steps in alphavirus replication. (A and B) Layout of time-of-addition
experiment with SFV and CHIKV. BHK-21 cells were infected with SFV (A) and CHIKV (B) at an MOI of 1
PFU/cell for 8 h and 14 h, respectively. OLX was present at 0.5 M for the different times indicated for
SFV (A) and CHIKV (B) infections. (C and D) Samples were collected from cultures receiving the different
treatments at 8 h p.i. for SFV (C) and at 14 h p.i. for CHIKV (D) and subjected to titration by the plaque
assay. The titers were compared to those of the untreated controls to obtain the log reduction in titers.
The values are representative of those from two independent experiments, and error bars represent
standard errors of the means.
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SFV-ts9 temperature-sensitive mutant. SFV-ts9 has a single point mutation in nonstruc-
tural protein 2 (nsP2; G389R) that results in multiple enzymatic defects in the N-terminal
region of the protein and prevents replication at the elevated temperature of 39°C (22,
23). SFV-ts9 was coupled with an Rluc reporter (SFV-ts9 –Rluc) and used to measure
signals only from the initial RNA genomes that entered and were translated by the
cellular machinery as a readout for viral entry. BHK-21 cells were infected with SFV-
ts9 –Rluc at 39°C and an MOI of 50 PFU/cell for 3 h and were either untreated or treated
at the same time with 0.1% DMSO, 0.5 M OLX, 25 M chlorpromazine (a known entry
inhibitor which causes defects in clathrin-mediated endocytosis) (24), or 50 nM bafilo-
mycin A1 (an inhibitor of vacuolar ATPase [vATPase] that leads to an increase in the
endosomal pH), which were present throughout the experiment (25, 26). OLX reduced
the luciferase signals to almost negligible levels, similar to the signals achieved with
bafilomycin A1, while chlorpromazine reduced the signals to 25% of the signals
achieved with the untreated control (Fig. 3A). A time-of-addition assay was also
performed with SFV-ts9. Pretreatment of cells with OLX for 120 min, 60 min, as well as
15 min prior to infection (treatment was discontinued postinfection) was sufficient to
reduce the luciferase signals to a large extent. On the other hand, OLX inhibited virus
entry to a lesser extent when it was added at 60 min p.i. than when it was added at the
same time or 15 min p.i. When it was added at 120 min p.i., the inhibition was abolished
(Fig. 3B). This set of results indicates that OLX, like bafilomycin A1, is an efficient
inhibitor of SFV entry and the entry defect happens rapidly during 15 min of treatment
of the cells.
Obatoclax disrupts the low-pH environment of acidic organelles. Due to the
significant effect of OLX on virus entry, similar to that of bafilomycin A1, we investigated
if the acidic environment of endosomal or lysosomal organelles is affected by OLX. The
autofluorescent nature of OLX (emission peak, 490 nm; absorbance peak, 550 nm) (19)
precluded any reliable conclusions from experiments using fluorescent pH-sensitive
dyes from being made (data not shown). Instead, we used the vital stain neutral red for
protonation and incorporation into acidic compartments, like lysosomes. The degree of
incorporation is inversely proportional to the lysosomal pH (27). A neutral red retention
assay was performed where HOS cells were loaded with 2.3 mM neutral red for 3 h in
medium without any phenol red and then treated with 0.1% DMSO or 0.5 M OLX.
Treated cells were imaged under a light microscope at intervals of 0, 5, 15, and 30 min
posttreatment (p.t.). For OLX-treated cells, the neutral red that had accumulated in
acidic organelles could be observed at 0 min p.t., and the staining was marginally
reduced at 5 min p.t. However, at 15 min p.t. and later, at 30 min p.t., there was a drastic
reduction in neutral red-positive organelles, suggesting neutralization of the endo-
somal acidic environment during OLX treatment. In comparison, neutral red staining in
cells treated with 0.1% DMSO remained unaffected when they were imaged at 30 min
p.t. (Fig. 4A).
For the alphaviruses, viral fusion at the plasma membrane can be triggered by
acidification of the extracellular medium (28). We tested if the inhibitory effect of OLX
could be rescued by bypassing the endosomal pH requirement. BHK-21 cells were
prechilled on ice for 10 min, followed by addition of the viral inoculum (SFV-ts9 –Rluc
at an MOI of 50 PFU/cell), and virus was allowed to bind to the plasma membrane for
30 min at 4°C. The viral inoculum was then aspirated, and cell-bound virus was pulsed
with buffer at pH 5.5 for 15 min at 39°C. The acidic buffer was then replaced with
neutral-buffered medium, and the cells were incubated for 3 h at 39°C and then
processed for the luciferase assay. Three different treatment schedules were used,
where 0.5 M OLX or 50 nM bafilomycin A1 was present throughout the course of the
experiment, added to the acidic buffer and being present thereafter, or added only
after the acidification step. For each treatment condition, appropriate DMSO-treated
controls were present. The inhibition that was normally seen with bafilomycin A1
treatment (Fig. 3A) was rescued by plasma membrane fusion regardless of the treat-
ment schedule used (Fig. 4B). On the other hand, the inhibition caused by OLX could
Varghese et al. Antimicrobial Agents and Chemotherapy
March 2017 Volume 61 Issue 3 e02227-16 aac.asm.org 6
 on A





































be rescued to the same extent only when the drug was added after the acid pulse
(Fig. 4B). Surprisingly, OLX addition to the acidic buffer itself caused some level of
neutralization, visualized by a color change in the acidic medium, which contained
phenol red as a pH indicator. Addition of OLX at 15 min p.i. was sufficient to inhibit viral
entry in the previous experiment (Fig. 3B). These results indicate that OLX indeed
induces rapid neutralization of the endosomal pH and this inhibitory effect of OLX can
indeed be reversed by inducing viral fusion at the plasma membrane.
Isolation of partially OLX-resistant SFV mutants. Next, we explored the possibility
of isolating OLX-resistant mutants to further characterize the compound’s mode of
action. BHK-21 cells were infected with wild-type SFV at a low MOI of 0.01 PFU/cell for
16 h in the presence or absence of 0.5 M OLX. These parameters were selected to
allow sufficient time for escape mutants to arise. Viral titers were estimated after the
FIG 3 Obatoclax inhibits SFV entry. The results of entry assays with temperature-sensitive mutant SFV-ts9
are shown. BHK-21 cells were infected with SFV-ts9 –Rluc at an MOI of 50 PFU/cell for 3 h at 39°C. At 3
h p.i., the cells were lysed and luciferase levels were measured. Values are expressed in relative luciferase
units, which is the percentage of luciferase units compared to the number of luciferase units for
untreated infected samples. Luciferase signals were measured from quadruplicate wells, and data are
presented as means  SEMs (n  2). (A) Cells were treated with infection medium or infection medium
containing 0.1% DMSO (solvent control), 0.5 M OLX, 25 M chlorpromazine, or 50 nM bafilomycin A1.
(B) (Top) Schema for the experiment, where BHK-21 cells were treated with 0.5 M OLX at different time
points before and after infection. (Bottom) Luciferase activity measured after the treatment schedules
shown in the top panel, identified by letters a to g, as compared to the untreated control set at 100%.
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FIG 4 Obatoclax neutralizes the acidic environment of endocytic organelles. A neutral red retention
assay was performed to assess the effect of OLX on endosomal acidification. (A) HOS cells were treated
with 2.3 mM neutral red in cell culture medium devoid of pH indicator for 3 h, followed by treatment with
0.1% DMSO or 0.5 M OLX. Images were captured at a 40 magnification and the indicated times using
a charge-coupled-device camera mounted on an Olympus CKX41 inverted light microscope and cellSens
software. (B) Endosomal acidification bypass by inducing plasma membrane fusion. Prechilled BHK-21
cells were infected with SFV-ts9 –Rluc at an MOI of 50 PFU/cell in neutral-buffered medium and allowed
to adsorb and bind to the plasma membrane for 30 min at 4°C. Plasma membrane fusion was triggered
by replacing the virus inoculum with acid-buffered medium for 20 min at 39°C, followed by replacement
with neutral-buffered medium and further incubation for 3 h at 39°C. Infected cells were treated with
0.1% DMSO, 0.5 M OLX, or 50 nM bafilomycin A1 according to the indicated schedules. At the end of
the incubation period, cells were lysed and luciferase levels were measured. Values are expressed in
relative luciferase units, which is the percentage of luciferase units compared to the number of luciferase
units for the DMSO-treated controls for each treatment schedule. Luciferase signals were measured from
triplicate wells, and data are presented as means  SEMs (n  3).
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first passage, and subsequent dilutions were adjusted to maintain approximately the
same MOI of 0.01 PFU/cell in every passage. Titrations were performed after every fifth
passage to check for phenotypic resistance, and subsequent passaging dilutions were
again adjusted to ensure the same MOI (see the schematic diagram in Fig. 5A). Partial
phenotypic resistance was seen after 30 rounds of passaging of SFV in the presence of
OLX. Multiple viral clones from the suspected resistant population were plaque purified,
cultured into fresh virus stocks, and tested once again for phenotypic resistance; an
increase in titer in the presence of OLX compared to the titer of the wild type was
observed. Two such resistant clones were subsequently sequenced, and four nonsyn-
onymous mutations, which were found in both of the resistant clones, were observed.
Two mutations were present in nonstructural protein 2 (nsP2; E46D and V601I), and two
were present in the E1 fusion glycoprotein (L369I and S395R).
Recombinant viruses which contained only the nsP2 mutations (designated the EV
mutant), only the E1 mutations (designated the LS mutant), or all four mutations
(designated the EVLS mutant) were constructed. Since OLX presumably inhibits viral
fusion by neutralizing the endosomal pH, we constructed additional recombinant
viruses by inclusion of the E1 L369I mutation in one virus (designated the L mutant) and
the S395R mutation in another virus (designated the S mutant). All these mutants were
tested for phenotypic resistance using the same parameters, and their resistance
profiles were compared with the resistance profile of the original resistant isolate. In
DMSO-treated cells, all mutant viruses grew to higher titers (2- to 6-fold) than the wild
type. However, in OLX-treated cells, the relative increment was more prominent (4- to
16-fold). The EV mutant as well as the LS mutant showed almost 10-fold increases in
viral titers compared to that of wild-type SFV in the presence of OLX (Fig. 5B). Viruses
with the combination of all four mutations (EVLS mutants) grew to approximately
15-fold higher titers, similar to the original resistant isolate (Fig. 5B). Unexpectedly, the
L mutant also showed the same level of resistance as the original isolate. On the other
hand, the S mutant showed only a 4-fold increase in titer (Fig. 5B). This result suggests
that the L369I mutation in the E1 fusion protein is sufficient to confer partial resistance
against OLX.
To further analyze the role of the mutations in the E1 fusion protein, we investigated
their effect in the SFV-ts9 entry assay. Mutants in which all the combinations of the E1
mutations (LS, L, and S) were cloned into SFV-ts9 –Rluc were generated. In an entry
assay performed in the absence of OLX, we observed a more than 2-fold increase in the
absolute luciferase signals for all three mutant combinations (LS, L, and S) compared to
that for wild-type SFV-ts9 –Rluc (Fig. 5C), suggesting that these mutations in the E1
protein were selected to confer an increased fusogenic ability. Next, a dose-response
entry assay was performed with BHK-21 cells infected with these SFV-ts9 –Rluc isolates
at an MOI of 50 PFU/cell and treated with OLX in a 3-fold dilution series ranging from
30 M to 0.002 M for 3 h at 39°C. In this assay, the virus containing only the L369I
mutation was less sensitive to OLX, with the EC50 for the virus with that mutation being
7-fold higher (0.5  0.02 M) than that for the wild type (0.07  0.02 M). The EC50s
of OLX for the other two mutants, the S and LS mutants, were higher (0.12  0.01 M
and 0.15  0.03 M, respectively) (Fig. 5D). Thus, results from the entry assay indicated
that the L369I mutation alone could mediate enhanced viral entry, even in the presence
of OLX, corroborating the previous result assessing viral titers (Fig. 5B).
Other drugs targeting the Bcl-2 family of proteins do not inhibit virus entry.
Next, we investigated if other compounds, like OLX, antagonizing the Bcl-2 family of
antiapoptotic proteins could also inhibit virus entry. We used TW-37, which has activity
against Bcl-2, Bcl-xL, and Mcl-1 (29), and another compound called venetoclax (also
known as ABT-199), which is a selective inhibitor of Bcl-2, Bcl-xL, and Bcl-w but has no
activity against Mcl-1 (30). These compounds were tested in the SFV-ts9 entry assay at
a concentration 10-fold higher than the concentration of OLX (5 M). The assay, where
BHK-21 cells were infected with SFV-ts9 –Rluc at an MOI of 50 PFU/cell for 3 h, also
included in parallel samples treated with 0.5 M OLX, 25 M chlorpromazine, and 50
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FIG 5 Partially obatoclax-resistant SFV mutants. (A) Passaging scheme employed for the isolation of
OLX-resistant SFV mutants in BHK-21 cells. P, passage. (B) BHK-21 cells were infected with wild-type SFV
and the respective mutant viruses in the presence of 0.1% DMSO or 0.5 M OLX. The viral titers in the
respective samples were determined. Values are represented as the fold increment in the viral titers
compared to the titer for the wild type for DMSO-treated and OLX-treated samples. Values are repre-
sentative of those from two independent experiments, and data are presented as means  SEMs (n 
2). (C) BHK-21 cells were infected with wild-type SFV-ts9 –Rluc and SFV-ts9 –Rluc isolates containing an E1
mutation at an MOI of 50 PFU/cell for 3 h at 39°C. At 3 h p.i., the cells were lysed and the luciferase levels
were measured. Luciferase levels are expressed as the fold increment in luciferase signals compared to
that for wild-type SFV-ts9 –Rluc. Luciferase signals were measured from quadruplicate wells, and data are
presented as means  SEMs (n  3). (D) Dose-response entry assay to evaluate the antiviral activity of
OLX. BHK-21 cells were infected with SFV-ts9 –Rluc and the corresponding E1 mutant viruses at an MOI
of 50 PFU/cell for 3 h at 39°C in the presence of OLX at concentrations ranging from 0.002 M to 30 M.
At 3 h p.i., the cells were lysed and luciferase levels were measured. Percent inhibition values were
calculated on the basis of the luciferase signals from infected cells treated with 0.1% DMSO. The
half-maximal threshold (the EC50) is marked with a dotted line. Assays were performed in triplicate wells.
Data are presented as means  SEMs (n  2).
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nM bafilomycin A1. Neither TW-32 nor ABT-199 inhibited the luciferase signals in this
assay (Fig. 6A), whereas we were able to recapitulate the data obtained earlier and
shown in Fig. 3A showing that OLX, chlorpromazine, and bafilomycin A1 significantly
inhibited SFV-ts9 entry. We also assessed the ability of these Bcl-2 inhibitors to disrupt
the endosomal acidic environment. Neither TW-37 nor ABT-199 affected neutral red
retention even after exposure for 6 h (Fig. 6B). This set of results suggests that the entry
block mediated by OLX through the neutralization of the endosomal pH is independent
of its antagonism of the Bcl-2 family of proteins.
The antiviral activity of obatoclax depends on the low-pH requirement of
different viruses. Finally, we assessed the effectiveness of OLX against other RNA
viruses from different families. We tested the activity of OLX against West Nile virus
(WNV) and yellow fever virus (YFV) (by infection of BHK-21 cells for 24 h, followed by
plaque assay titration of viral particles in the supernatants of infected cells) as well as
a novel stable reporter Zika virus (ZIKV) (by infection of Vero E6 cells for 72 h, followed
by measurement of NanoLuc reporter activity in the lysates of infected cells). WNV, YFV,
and ZIKV are members of the Flaviviridae family possessing a class II fusion protein and
have been shown to require a low pH for membrane fusion (8). We also employed
viruses from the Picornaviridae family that do not have a clear acidification requirement
in their entry process, like coxsackievirus A9 (CV-A9) (31), echovirus 6 (E-6), and
echovirus 7 (E-7) (for the infection protocol, refer to the Materials and Methods section)
(32). WNV, YFV, and ZIKV were highly sensitive to OLX treatment, with the EC50s for
these viruses being low (0.13 M) and the selectivity indices being high (Table 2; Fig.
S4). On the contrary, OLX showed 30-fold higher EC50s for the pH-insensitive picor-
FIG 6 Bcl-2 inhibitors do not affect virus entry or endosomal acidification. (A) BHK-21 cells were infected
with SFV-ts9 –Rluc at an MOI of 50 PFU/cell for 3 h at 39°C. Infected cells were untreated or treated with
0.1% DMSO (solvent control), 0.5 M OLX, 25 M chlorpromazine, 50 nM bafilomycin A1, 5 M TW-37,
or 5 M ABT-199. At 3 h p.i., cells were lysed and luciferase levels were measured. Values are expressed
in relative luciferase units, which is the percentage of luciferase units compared to the number of
luciferase units for untreated infected samples. Luciferase signals were measured from quadruplicate
wells, and data are presented as means  SEMs (n  2). (B) HOS cells were treated with 0.66 g/liter of
neutral red in cell culture medium devoid of pH indicator for 3 h, followed by treatment with 0.1% DMSO,
50 nM bafilomycin A1, 5 M TW-37, or 5 M ABT-199. Images were captured at a 40 magnification and
the indicated times using a charge-coupled-device camera mounted on an Olympus CKX41 inverted light
microscope and cellSens software.
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naviruses CV-A9, E-6, and E-7 than for the flaviviruses, and the selectivity indices were
marginal (Table 2; Fig. S5).
DISCUSSION
OLX is a synthetic indole bipyrrole derivative of bacterial prodigiosin and was
developed as a BH3 domain mimetic that inhibits the Bcl-2 family of prosurvival
proteins (19, 33). It has been in clinical trials for the treatment of a wide variety of
cancers either as a monotherapeutic treatment or in combination with other anticancer
compounds (34). OLX was found to be effective against IAV at submicromolar concen-
trations (EC50  0.014 M) and was proposed to inhibit IAV entry or internalization by
targeting Mcl-1 (20). However, we show here for the first time that the antiviral property
of OLX is its ability to rapidly neutralize the pH in acidic endosomes or lysosomes. This
low-pH environment is necessary for the fusion or uncoating of viruses from diverse
families and is thus considered a broad-spectrum host target for antiviral compounds.
Indeed, OLX also inhibited other pH-dependent viruses of the Flaviviridae family at
submicromolar concentrations, whereas viruses like CV-A9, which utilizes nonacidic
multivesicular bodies for entry (31), and other pH-independent viruses, like E-6 and E-7,
were unaffected by OLX treatment (Table 2). Also, it was shown earlier that OLX could
not inhibit or prevent virus-induced cytotoxicity caused by a low-pH-independent
enveloped virus like measles virus (20).
OLX was able to efficiently inhibit three different Old World alphaviruses (Fig. 1A),
suggesting that the compound inhibits a common feature required by these viruses.
This inhibition was also evident under high-MOI conditions, where virus particle
production (Fig. 1B), viral protein expression (Fig. 1C), and RNA synthesis (Fig. 1D) were
concomitantly impeded. Next, time-of-addition experiments with SFV were used to
highlight the predominant effect of OLX on the early phase of the viral infectious cycle
(Fig. 2C), with similar results being obtained for CHIKV (Fig. 2D). These results were
corroborated by the results of an entry assay using the temperature-sensitive SFV-ts9 –
Rluc virus as a readout for virus entry. In that assay, OLX almost completely blocked the
luciferase signals emanating only from the translation of viral genomes that had
entered the host cells (Fig. 3A). A time-of-addition assay with SFV-ts9 showed that the
effect was maximal when cells were pretreated with OLX. The inhibition was prevalent
even when OLX was added at 15 min p.i. and corresponds well with the fusion time
scale for both SFV (35) and CHIKV (36).
OLX brought about the rapid neutralization of the acidic environment in endo-
somes/lysosomes within 15 to 30 min of exposure (Fig. 4). Indeed, three recent reports
have provided independent corroboration of our findings and showed that OLX not
only increases the lysosomal pH but also accumulates in the lysosomes and causes a
loss of lysosomal function (37–39). The fact that OLX is a weak base and the likelihood
that it is protonated and accumulates in lysosomes, similar to another lysomotrophic
agent, chloroquine, suggest a possible mechanism for the rapid elevation in the
lysosomal pH (38). Additionally, Champa et al. have suggested that OLX could mediate
the exchange of Cl and HCO3 ions between the cytoplasm and the lysosome, which
would also cause a rapid elevation in the lysosomal pH (37). Interestingly, addition of
as little as 0.5 M OLX to the acidic medium during endosomal bypass elevated the pH
TABLE 2 EC50s of obatoclax against pH-dependent and -independent viruses
Virus EC50a (M) CC50b (M) SIc
WNV 0.10  0.04 20 200
YFV 0.125 20 160
ZIKV 0.13  0.01 6.6  4.4 50.77
CV-A9 2.95  0.01 13.47  0.04 4.57
E-6 4 13.47  0.04 3.37
E-7 3.9  0.32 13.47  0.04 3.45
aEC50, concentration causing 50% inhibition of viral replication.
bCC50, concentration causing a 50% reduction in cell survival.
cSI, selectivity index, which is the ratio of the CC50 to the EC50.
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and resulted in only a minimal rescue, whereas addition of OLX after plasma membrane
fusion resulted in lower levels of inhibition, similar to the findings observed with
bafilomycin A1 (Fig. 4B). This serves to underline the mildly basic nature of OLX.
Consistent with what other groups have observed (37), the ability of OLX to
neutralize acidic organelles is independent of its ability to inhibit the Bcl-2 family of
prosurvival proteins. Another pan-Bcl-2 inhibitor, TW-37, as well as a selective antag-
onist of Bcl-2, ABT-199, could neither block virus entry (Fig. 6A) nor disrupt neutral red
staining of acidic organelles, even when they were used to treat cells for 6 h at
concentrations 10-fold higher than the concentration of OLX (Fig. 6B). OLX induced
lysosome clustering in some cell types (39), but in some others it affected the lysosomal
pH without causing the obvious destruction of these organelles (37). Nevertheless, the
precise mechanism by which OLX brings about such a swift loss in lysosomal acidity
remains to be determined.
The barrier for resistance development may be high when a host process essential
for the viral life cycle is targeted. The fusion of viral and endosomal membranes,
triggered by low-pH-induced conformational changes in the fusion protein, is one such
critical step in the viral entry process. In this work, it took 30 rounds of passaging of SFV
in the presence of OLX to obtain only partially resistant mutants. The resistant mutants
grew to titers more than 1 log higher than the titer of wild-type SFV in the presence of
OLX, but they did not reach titers as high as those of wild-type virus in untreated cells.
The mutations L369I (in E1 domain III) and S395R (in the E1 stem region) were found
in the E1 membrane fusion protein, providing indirect evidence that OLX affects virus
membrane fusion-related processes. The L369I mutation alone was sufficient to confer
the resistance phenotype both when viral titers in the presence of OLX were assessed
(Fig. 5B) and also in a dose-response entry assay (Fig. 5D). Even though mutants with
all three combinations of the E1 mutations appeared to have an increased fusogenic
potential (Fig. 5C), the presence of the S395R mutation seemed to dampen the effect
of the L369I mutation, as the LS mutant showed only an 8-fold increase in viral titers
in the presence of OLX (Fig. 5B) and the EC50 of OLX for the LS mutant was increased
only 2-fold compared to that for wild-type SFV-ts9 –Rluc (Fig. 5D). This suggests that
there could be possible interactions between these two residues (L369 and S395) in the
E1 fusion protein. Further phenotypic analysis is required to fully elucidate the func-
tionality of these residues. Interestingly, a 10-fold increase in the titer of the EV nsP2
mutant was also found when it was treated with OLX (Fig. 5B). Earlier, serial passage of
CHIKV for only 7 rounds in HeLa cells was enough for cell culture adaptation, resulting
in increased fitness and resistance to a cocktail of antiviral mutagens (40). This was also
seen with hepatitis C virus, where increased viral fitness led to reduced drug sensitivity
(41). It is therefore possible that although the chief mode of action of OLX is the
neutralization of the endolysosomal acidic environment, additional fitness mutations
might have emerged during the selection process.
The EC50s of OLX for CHIKV in the different cell lines tested were in the range of 0.04
to 0.15 M. When OLX was given as 3-h infusions in clinical studies, plasma OLX
concentrations reached a maximum of 0.4 M (42, 43), suggesting that an effective
therapeutic dose for prophylaxis against CHIKV and treatment of CHIKV infection can be
envisaged. Chloroquine, a known lysomotrophic agent which has anti-CHIKV activity at
concentrations (range, 5 to 20 M) higher than those of OLX in vitro (11), did not
demonstrate a selective advantage over a nonsteroidal anti-inflammatory drug, but the
possibility that it has therapeutic efficacy was not ruled out (44). Further studies need
to be performed in a suitable mouse model of CHIKV infection to ascertain the antiviral
potential of OLX. Additionally, given the effectiveness of OLX against WNV, YFV, and
ZIKV, it would be interesting to investigate if OLX is effective in animal models of these
diseases (especially Zika fever), as well as against DENV, which affects millions of
individuals every year. In conclusion, OLX is a promising compound for repurposing as
an antiviral candidate and is effective against several pathogenic viruses at submicro-
molar concentrations.
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Cells and inhibitors. Baby hamster kidney (BHK-21) and human osteosarcoma (HOS) cells were
grown as described earlier (45, 46). Human hepatoma (Huh 7.5) cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS; Gibco) supplemented with
nonessential amino acids, penicillin, streptomycin, and L-glutamine (Gibco). Vero E6 African green
monkey kidney cells were cultured in Iscove’s modified Dulbecco’s medium (IMDM) containing 10% FBS.
Human epithelial lung carcinoma (A549) cells (ATCC) were grown in DMEM containing 10% FBS
supplemented with gentamicin. All cells were maintained at 37°C with 5% CO2. Obatoclax (Selleckchem),
chlorpromazine (Calbiochem), bafilomycin A1 (Sigma), TW-37 (Selleckchem), ABT-199 (Selleckchem) were
dissolved in dimethyl sulfoxide (DMSO) and used at the concentrations indicated above.
Viruses. The infectious cDNA clones of wild-type SFV (47) and SINV (48) used in this study have been
described earlier. Wild-type CHIKV (strain LR2006 OPY1) was generated from the infectious clone
SP6-ICRES (21). SFV-Rluc and CHIKV-Rluc were derived from the respective wild-type clones, where the
Renilla reniformis luciferase gene (Rluc) is inserted within the nsP3-coding region (21). The method used
to generate SFV-ts9 –Rluc, which has a point mutation in nsP2 and which carries the Rluc reporter, has
been described earlier (21). SFV mutants were generated by subcloning the respective regions (between
the SacI and XbaI sites in the pUC18 vector for the nsP2 mutations and two PsiI sites in the pUC57 vector
for the E1 mutations) from plasmid pCMV-SFV4 (49) and performing site-directed mutagenesis using a
QuikChange Lightning multi-site-directed mutagenesis kit (Agilent). The synthesized clones were se-
quenced and cloned back into the original pCMV-SFV4 vector. All alphavirus stocks were produced in
BHK-21 cells, and viral titers were quantified by conventional plaque assay titration (21).
The details of the construction and properties of Zika virus (ZIKV) clone ZIKV-UbiNanoLuc derived
from infectious cDNA (icDNA) will be described elsewhere. Briefly, the icDNA of ZIKV was obtained by
assembly of synthetic cDNA fragments (GenScript, USA) corresponding to the sequence of the ZIKV Asian
genotype, isolated in Brazil in 2015 (isolate BeH819015); the sequences of the 5= and 3= untranslated
regions (UTRs), not fully resolved in the published sequence of the isolate (GI|975885966), were
completed on the basis of the sequence of ZIKV isolate PE243/2015 from Brazil (GI|1026288139).
Full-length cDNA, placed under the control of the bacteriophage SP6 RNA polymerase promoter, was
assembled in the pCC1BAC vector by use of a CopyControl cloning kit (Epicentre, USA). Insertion of the
sequence encoding the NanoLuc reporter was carried out by a method similar to that previously
described for the icDNA clone of DENV (50). ZIKV-UbiNanoLuc was rescued in Vero cells that had been
transfected with capped transcripts generated by SP6 RNA polymerase; the titers of the rescued virus
were determined by plaque titration in Vero cells. ZIKV-UbiNanoLuc was subsequently passaged 5 times
at a multiplicity of infection (MOI) of 0.1 PFU/cell; NanoLuc activities in infected cells were measured at
different passages using a Promega Renilla luciferase assay system and were found to be constant,
indicating that the obtained virus stock was genetically stable. West Nile virus (WNV; isolate NY
2000-crow3356) was grown on BHK-21/J cells and titers were determined as described previously for
yellow fever virus (YFV) (51). Infectious cDNA clone 17D of YFV has been described earlier (52). The
prototype picornaviruses used in this study included coxsackievirus A9 (CV-A9; GenBank accession
number D00627), echovirus 6 (E-6; GenBank accession number AY302558), and echovirus 7 (E-7; GenBank
accession number AY036578).
SDS-PAGE and Western blotting. Analysis of CHIKV protein expression was performed as described
earlier (45). Briefly, BHK-21 cells were infected with wild-type CHIKV in the format described above for the
assay whose results are presented in Fig. 1C. Solubilized cell lysates were separated on a 10% SDS-
polyacrylamide gel and blotted onto a Hybond enhanced chemiluminescence nitrocellulose membrane
(GE Healthcare). Primary staining was performed using rabbit anti-CHIKV nsP1, nsP3, and capsid anti-
bodies (all of which were prepared in-house), mouse anti-CHIKV E2 monoclonal antibody 3E4 (53), and
mouse antiactin (Sigma). Alexa Fluor 680-conjugated anti-rabbit (Invitrogen) and IRDye800-conjugated
anti-mouse (LI-COR Biosciences) antibodies were used for secondary staining, and the blots were
scanned using an Odyssey infrared imaging system (LI-COR Biosciences).
Northern blotting. BHK-21 cells seeded on 6-well plates were infected with wild-type CHIKV in the
presence of serial dilutions of OLX as described above for the assay whose results are presented in Fig.
1D. At 6 h p.i., total RNA was isolated from the respective wells using the TRIsure reagent (Bioline)
according to the manufacturer’s instructions. CHIKV genomic and subgenomic RNAs were detected using
a digoxigenin (DIG)-labeled RNA probe designed against the 3= UTR of the viral genome, as described
earlier (54).
Antiviral activity assay. Ninety-six-well white-bottom culture plates (PerkinElmer) were seeded with
BHK-21 cells, HOS cells, or Huh 7.5 cells. On the next day, the cells were infected with SFV-Rluc or
CHIKV-Rluc at the MOIs indicated in the Results in the presence of OLX at concentrations ranging from
0.007 M to 100 M. After the respective incubation times (see the Results section), the cell culture
supernatant was discarded, the cells were lysed, and the luciferase signals were measured using a Renilla
luciferase assay system (Promega) and detected with a Varioskan Flash multimode reader (Thermo Fisher
Scientific) according to the manufacturers’ instructions.
Cell viability assays. BHK-21, HOS, or Huh 7.5 cells seeded on 96-well white-bottom culture plates
(PerkinElmer) were treated with OLX at various concentrations ranging from 0.007 M to 100 M. After
incubation, the cell culture supernatant was removed, the cells were washed with phosphate-buffered
saline (PBS), and cell viability was measured using the CellTiter-Glo reagent (Promega), which measures
cellular ATP levels from metabolically active cells. For infections with flaviviruses, cell viability was
measured in parallel using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay
(Sigma). Briefly, BHK-21 cells were treated with OLX at concentrations ranging from 20 M to 0.016 M.
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MTT was added to the supernatant at a final concentration of 200 g/ml, and incubation was continued
at 37°C for 90 min. After the cells were fixed with 4% formaldehyde, the cells were dissolved in
isopropanol and colorimetric measurement was performed at an optical density of 562 nm. For infections
with picornaviruses, cell viability was measured in parallel using a cell counting kit-8 (CCK-8; Dojindo)
according to the manufacturer’s instructions.
Endosomal bypass assay. BHK-21 cells seeded on 96-well plate culture plates were prechilled on ice
for 10 min, followed by addition of virus inoculum (SFV-ts9 –Rluc) in neutral-buffered medium (minimal
essential medium containing 0.2% bovine serum albumin [BSA], 20 mM HEPES buffer [pH 7.2], and 1%
L-glutamine). The virus in the inoculum was allowed to adsorb and bind to the plasma membrane for 30
min at 4°C. The viral inoculum was then discarded, followed by induction of plasma membrane fusion
by addition of acidic medium (minimal essential medium containing 0.2% BSA, 10 mM morpholine-
ethane sulfonic acid [pH 5.5] and 1% GlutaMAX-1 [Invitrogen]) and incubation for 15 min at 39°C. The
acidic medium was then replaced with neutral-buffered medium and incubated further for 3 h at 39°C,
followed by cell lysis and analysis of luciferase signals as described above.
Plaque purification of resistant mutants. BHK-21 cells seeded on 6-well plates were infected with
the suspected resistant stocks in a 10-fold serial dilution format in the presence of 0.5 M OLX. After 1
h of adsorption, the virus inoculum was discarded, the cells were washed with PBS, and overlay medium
containing minimal essential medium without phenol red, 1% Bacto agar, 4% FBS, nonessential amino
acids, penicillin, streptomycin, and L-glutamine was added (4 ml/well). At 48 h p.i., overlay medium
containing neutral red stain (82.5 mg/liter) was added to enable the visualization of plaques. At 72 h p.i.,
plugs of plaques from wells with the highest dilution showing visible plaques were purified, and the
purified plaques were stored at 80°C. All media contained 0.5 M OLX to maintain a constant selection
pressure.
Sequencing. Viral RNA from phenotypically resistant plaque-purified stocks was isolated using a viral
RNA minikit (Qiagen). cDNAs were synthesized using random primers and the viral RNA as a template
with a high-capacity cDNA reverse transcription kit (Applied Biosystems). PCR products spanning the
entire SFV genome were generated using the cDNAs as the templates and sequenced by standard
Sanger sequencing. The sequenced contigs were assembled using BioEdit software (v7.2.5), and the
sequence was compared to the genomic sequence of wild-type strain SFV4.
Picornavirus infection assays. A549 cells were seeded on 96-well plates (PerkinElmer) with cell
culture medium and incubated for 24 h. The cells were washed twice with phosphate-buffered saline,
and OLX was added to the cells at concentrations ranging from 0.05 M to 4 M for 30 min. The cells
were infected with the viruses in five replicates for 1 h on ice. This was followed by three washes with
medium and addition of DMEM supplemented with 1% FBS with the same concentrations of OLX. At 6
h p.i., the cells were fixed with 4% formaldehyde, permeabilized with 0.2% Triton X-100, and stained with
virus type-specific antibodies (from laboratory collections). Virus staining was visualized with secondary
Alexa Fluor 488 antibodies and an Evos FL Auto microscope (Thermo Fisher). Infection efficiencies were
analyzed with BioImageXD software (55).
Data and statistical analysis. Half-maximal (50%) effective and cytotoxic concentrations (EC50 and
CC50, respectively) were determined using GraphPad Prism software by generating antiviral and cell
survival curves. Statistical analyses were done using Microsoft Excel software. Statistical significance was
determined using a one-way analysis of variance (ANOVA) test. P values of less than 0.05 were considered
statistically significant.
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